Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Piramal has entered into an agreement with G&W Laboratories to acquire its solid oral dosage drug product manufacturing facility located in Sellersville, Pennsylvania.
read more
Tuesday, December 16, 2025
Piramal Pharma Solutions has achieved a Net Promoter Score (NPS) of 55 for the time period representing FY2025 (April 2024 – March 2025).
read more
Tuesday, January 13, 2026
Piramal Pharma Limited (PPL) announced it achieved a score of 63 on the 2025 S&P Global CSA. This marks a substantial 15% improvement over last year’s score of 55, reflecting the company's ongoing commitment to sustainability and responsible ...
read more
Tuesday, December 08, 2020
Piramal Pharma Limited has announced plans to expand its facility in Michigan with additional capacity and new capabilities for the development and manufacturing of APIs.
read more
Tuesday, September 29, 2020
Piramal Pharma held a grand opening event at their recently acquired solid oral dosage drug product manufacturing facility located in Sellersville, Pennsylvania.
read more
Piramal Healthcare Limited [NSE: PIRHEALTH, BSE: 500302], an innovation led company, has agreed to acquire Decision Resources Group a US based company in the healthcare information segment, from Providence Equity Partners for a consideration of ...
read more
Piramal Healthcare Limited [NSE: PIRHEALTH, BSE: 500302] ("Piramal"), announced that it has signed an agreement to acquire worldwide rights to the molecular imaging research and development portfolio of Bayer Pharma AG ("Bayer") through its newly ...
read more
Wednesday, October 14, 2015
Piramal Enterprises' Pharma Solutions division, a global contract development and manufacturing organization (CDMO), has delivered its comprehensive review of the injectables market – both sterile and small molecule – for the next 5 years during its ...
read more
Wednesday, September 30, 2015
Piramal Enterprises' Pharma Solutions division, a global contract development and manufacturing (CDMO) company, has set a target of becoming the market leader in ADCs contract commercialization over the next five years.
read more
Thursday, November 17, 2022
Piramal Critical Care (PCC) has integrated its sustainability framework with its strategy as well as daily business practices.
read more
Piramal Critical Care announced the launch of MITIGO™ (Morphine Sulfate Injection, USP – Preservative-free) in 10 mg/mL and 25 mg/mL concentrations in the U.S. market.
read more
Piramal Critical Care, an integral business unit of Piramal Enterprises Limited and Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company focused on hospital acute care and gastroenterology, have officially launched a co-promotion of ...
read more
Piramal Pharma Limited’s Piramal Critical Care (PCC) business announced the appointment of Jeffrey Hampton as President & Chief Operating Officer (COO). For his new role, Mr. Hampton will be based in the United States.
read more
Tuesday, October 10, 2017
Piramal announced investments of $55 million across its sites in North America & Asia, to expand its API manufacturing capabilities and capacities.
read more
Piramal is providing Bolt with the supply of both the BDC-1001 ISAC drug substance and the drug product for Bolt's ongoing Phase 1/2 clinical study in cancer patients.
read more